- Global Pharma News & Resources

Outlook on the Healthcare Contract Development & Manufacturing Organization Global Market to 2026 - Competitive Analysis and the Impact of COVID-19 -

DUBLIN--(BUSINESS WIRE)--The "Global Healthcare Contract Development & Manufacturing Organization Market (2021-2026) by services, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis" report has been added to's offering.

The Global Healthcare Contract Development & Manufacturing Organization Market is estimated to be USD 209.5 Bn in 2021 and is expected to reach USD 314.8 Bn by 2026, growing at a CAGR of 8.5 %.

Key factors, such as the growing number of new molecular entities have led to a demand for high-end technical expertise. Also, at given times, to expedite the drug manufacturing process, pharma companies are depending on CDMOs for their niche technical expertise to get the product in the market. In addition to it, companies are equally focusing on reducing the capital expenditure involved in manufacturing processes. These factors are prominently driving the growth of the contract development and manufacturing organization (CDMO) market.

However, the serialization issues along with the infringement issues related to intellectual property are likely to restrain the market growth.

Company Profiles

Some of the companies covered in this report are Lonza Group Ltd.; Recipharm AB; Siegfried Holding AG; Covance Inc.; Jabil; Sanmina Corporation; IQVIA Holdings Inc.; and Flex.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Healthcare Contract Development & Manufacturing Organization Market.
  • The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
  • The report also contains the competitive analysis using the Competitive Quadrant, the analyst's Proprietary competitive positioning tool.

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Overview

4.1 Introduction

4.2 Market Dynamics

4.2.1 Drivers Need of a high-level expertise to expedite drug manufacturing process Focus of the pharmaceutical companies towards reducing their operational expenses Increasing complexity with the development of new molecular entities

4.2.2 Restraints Serialization issues faced by healthcare organizations Issues related to infringement of Intellectual Property (IP) rights

4.2.3 Opportunities Rise in the drug approvals cases Technological Advancements Increasing collaborations and investments by CDMOs

4.2.4 Challenges Compliance issues while outsourcing

4.3 Trends

5 Market Analysis

5.1 Porter's Five Forces Analysis

5.2 Impact of COVID-19

5.3 Ansoff Matrix Analysis

6 Global Healthcare Contract Development & Manufacturing Organization Market, By Service

6.1 Introduction

6.2 Contract Development

6.2.1 Preclinical Bioanalysis and DMPK studies Toxicology Testing Other Preclinical Services

6.2.2 Clinical Phase I Phase II Phase III Phase IV

6.2.3 Laboratory Services Bioanalytical Services Analytical Services

6.3 Contract Manufacturing

6.3.1 API/Bulk Drugs

6.3.2 Finished Dose Formulations

6.3.3 Medical Device Class I Class II Class III

7 Global Healthcare Contract Development & Manufacturing Organization Market, By Solution Type

7.1 Introduction

7.2 North America

7.3 South America

7.4 Europe

7.5 Asia-Pacific

7.6 Rest of the World

8 Competitive Landscape

8.1 Competitive Quadrant

8.2 Market Share Analysis

8.3 Competitive Scenario

8.3.1 Mergers & Acquisitions

8.3.2 Agreement, Collaborations, & Partnerships

8.3.3 New Product Launches & Enhancements

8.3.4 Investments & Fundings

9 Company Profiles

9.1 AbbVie Inc.

9.2 Almac Group Ltd.

9.3 Baxter International, Inc.

9.4 B. Braun Melsungen AG

9.5 Boehringer Ingelheim International GmbH

9.6 Catalent Inc.

9.7 Covance Inc.

9.8 Cambrex Corp. (Permira Funds)

9.9 Hisun Pharmaceuticals Inc.

9.10 Jabil Inc.

9.11 Jubilant Life Sciences Ltd.

9.12 IQVIA Holdings Inc

9.13 Flex

9.14 Lonza Group Ltd.

9.15 Mikart LLC (Nautic Partners)

9.16 Pfizer Inc.

9.17 Probiogen AG (Minapharm Pharmaceuticals)

9.18 Recipharm AB

9.19 Siegfried Holding AG

9.20 Sanmina Corp.

9.21 Stason Pharmaceuticals, Inc.

9.22 Thermo Fisher Scientific Inc.

10 Appendix

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 24-Oct-2021